Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry‐based study

Amichai Berkovitz, Rachael D. Migler, Adam Qureshi, Carly Rosemore, Michael S. Torbenson, Roger Vaughan, Erin Marcotte, Sanford M. Simon – 16 October 2022 – Fibrolamellar hepatocellular carcinoma (FLC) is a rare primary liver cancer that affects primarily adolescents and young adults. It is associated with a poor overall prognosis. There is a need to better define risk factors, but small sample size has limited such studies. An FLC patient registry now provides data sufficient for statistically robust inferences.

Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancers

Scott McHenry, Xiaoyu Zong, Mengyao Shi, Cassandra D.L Fritz, Katrina S. Pedersen, Linda R. Peterson, Jeffrey K. Lee, Ryan C. Fields, Nicholas O. Davidson, Yin Cao – 10 October 2022 – Metabolic syndrome may contribute to the rising incidence of multiple gastrointestinal (GI) cancers in recent birth cohorts. However, other than hepatocellular carcinoma, the association between nonalcoholic fatty liver disease (NAFLD) and risk of non‐liver GI cancers is unexplored.

Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascites

Cristina Ripoll, Luis Ibáñez‐Samaniego, Beatrix Neumann, Javier Vaquero, Robin Greinert, Rafael Bañares, Alexander Zipprich – 10 October 2022 – The aim of this study was to evaluate potential criteria for defining hyperdynamic circulation in patients with cirrhosis according to the severity of ascites and its association with the activation of vasoactive systems and markers of systemic inflammation. Cross‐sectional study of patients with cirrhosis and right heart catheter measurement from two different academic centers.

HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB‐4 scores

Tung Huynh, Stephanie Ma, Ke‐Qin Hu – 10 October 2022 – Direct acting antiviral treatment (DAA) has been the standard of care for hepatitis C virus (HCV) infection, but its long‐term benefits in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) improvement and hepatic fibrosis assessed by aspartate aminotransferase–to–platelet ratio index (APRI) and Fibrosis‐4 index (FIB‐4) scores remain unknown.

Subscribe to